Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Soo-Kyung | - |
dc.contributor.author | Kim, Dam | - |
dc.contributor.author | Won, Soyoung | - |
dc.contributor.author | Lee, Jiyoung | - |
dc.contributor.author | Park, ByeongJu | - |
dc.contributor.author | Jang, Eun Jin | - |
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Sung, Yoon-Kyoung | - |
dc.date.accessioned | 2021-07-30T04:58:19Z | - |
dc.date.available | 2021-07-30T04:58:19Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-02 | - |
dc.identifier.issn | 0049-0172 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2421 | - |
dc.description.abstract | Objectives: To estimate the incidence of cardiovascular disease (CVD) in Asian patients with rheumatoid arthritis (RA) and to evaluate the impact of anti-rheumatic treatment on the development of CVD. Methods: A retrospective cohort of Asian patients with RA was established to identify the incidence rate (IR) of CVD in RA patients. The cohort was generated using the Korean National Healthcare claims database, which contained claims from Jan 2009 to Dec 2013. A total of 137,512 RA patients were identified; individuals with a history of CVD for 6 months or more before the index date were excluded. Nested case-control samples were drawn from the full study population with a case:control ratio of 1:4 (n = 7102 cases; n = 27,018 controls without CVD). A conditional multivariate regression model was used to evaluate the impact of anti-rheumatic treatment on the development of CVD in RA patients after matching for age, sex, RA index date, comorbidities, and drug use (e.g., antiplatelet agents and cholesterol-lowering agents). Results: The IR for development of overall CVD in RA patients was 182.1 (95% CI: 178.4-185.9) per 10,000 person-years. In models adjusted for other CVD risk factors, disease-modifying anti-rheumatic drugs (DMARDs) (OR = 0.79) were protective against CVD, and biologic DMARDs were not significantly associated with CVD risk (OR = 0.85). Corticosteroids (OR = 1.26) and NSAIDs (nonselective NSAIDs: OR = 1.32, Cox-2 inhibitors: OR = 131) were risk factors for CVD in RA patients. Conclusions: The use of DMARDs is protective against CVD, while corticosteroids and NSAIDs increased the risk of CVD in RA patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | W B SAUNDERS CO-ELSEVIER INC | - |
dc.title | Impact of anti-rheumatic treatment on cardiovascular risk in Asian patients with rheumatoid arthritis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cho, Soo-Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Dam | - |
dc.contributor.affiliatedAuthor | Bae, Sang-Cheol | - |
dc.contributor.affiliatedAuthor | Sung, Yoon-Kyoung | - |
dc.identifier.doi | 10.1016/j.semarthrit.2017.08.002 | - |
dc.identifier.scopusid | 2-s2.0-85028464896 | - |
dc.identifier.wosid | 000419811200007 | - |
dc.identifier.bibliographicCitation | SEMINARS IN ARTHRITIS AND RHEUMATISM, v.47, no.4, pp.501 - 506 | - |
dc.relation.isPartOf | SEMINARS IN ARTHRITIS AND RHEUMATISM | - |
dc.citation.title | SEMINARS IN ARTHRITIS AND RHEUMATISM | - |
dc.citation.volume | 47 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 501 | - |
dc.citation.endPage | 506 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | ACUTE MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | DISEASE-ACTIVITY | - |
dc.subject.keywordPlus | INFLAMMATORY POLYARTHRITIS | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | COHORT | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Cardiovascular disease | - |
dc.subject.keywordAuthor | DMARDs | - |
dc.subject.keywordAuthor | NSAIDs | - |
dc.subject.keywordAuthor | Corticosteroids | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0049017217301658?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.